


# The meriT-3 Study

## Study Highlights

- Principal Investigator: Dr. Rajendra Kumar Jain
- The meriT-3 was a multi-centre, observational, post-marketing study conducted in 1161 patients with coronary artery disease (CAD) who were implanted with BioMime SES at 15 sites in India
- The meriT-3 study demonstrated safety and efficacy of BioMime SES in patients with CAD in real world scenario



## ❖ Study Design

A multi-centre, observational, real world study





A total 1161 patients who were implanted with BioMime SES



Clinical/telephonic follow-up at 1-month, 6-months and 12-months

❖ Clinical Outcomes



## ❖ References

1. ClinicalTrials.gov –  
<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=15417&EncHid=&userName=CTRI/2017/10/009968>
2. Jain RK, Chakravarthi P, Shetty R, Ramchandra P, Polavarapu RS, Wander GS, Mohan B, Banker DN, Dharmadhikari A, Bansal SS, Jain N. One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study. *Indian heart journal*. 2016; 68 (5):599-603.
3. Nagic J, McCormick LM, Francis R, Nerlekar N, Jaworski C, West NE, Brown AJ. Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. *Journal of cardiology*. 2018; 71(5):435-443.
4. Bhatt S, Gujarathi S, De Benedictis M. Innovative DES technologies from Meril. *Minerva cardioangiologica* 2015; 63:441-8.
5. Presented by R. K. Jain. One year Outcomes of a BioMime sirolimus-eluting coronary stent system with a Biodegradable polymer in all comers coronary artery disease patients: The meriT-3. At Asia PCR 2017.
6. Presented by Praveen Chandra. My Experience with BioMime Family of SES. At TCT 2017.
7. Presented by Roberto Botelho. Outcomes With a Thin-Strut PLLA-Based Sirolimus-Eluting Stent 1: BioMime. At TCT 2017.  
<https://www.tctmd.com/slide/outcomes-thin-strut-plla-based-sirolimus-eluting-stent-1-biomime>